BriaCell Therapeutics Faces Delisting Concerns
Ticker: BCTXZ · Form: 8-K · Filed: Jul 5, 2024 · CIK: 1610820
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
Related Tickers: BCTX
TL;DR
BriaCell might get delisted, stock could tank.
AI Summary
BriaCell Therapeutics Corp. filed an 8-K on July 5, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company's former name was Ansell Capital Corp., and it changed its name on June 13, 2014. The filing indicates potential issues with the company's continued listing on the stock exchange.
Why It Matters
This filing signals potential delisting for BriaCell Therapeutics, which could significantly impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading on an exchange.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- July 3, 2024 (date) — Earliest event reported
- July 5, 2024 (date) — Filing date
- June 13, 2014 (date) — Date of name change
FAQ
What specific listing rule or standard has BriaCell Therapeutics Corp. failed to satisfy?
The filing does not specify the exact rule or standard that BriaCell Therapeutics Corp. has failed to satisfy, only that it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard'.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing is July 3, 2024.
When did BriaCell Therapeutics Corp. change its name from Ansell Capital Corp.?
BriaCell Therapeutics Corp. changed its name from Ansell Capital Corp. on June 13, 2014.
What is the company's primary business as indicated by its SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to 'Pharmaceutical Preparations'.
What is the filing date of this 8-K report?
This 8-K report was filed on July 5, 2024.
Filing Stats: 604 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-07-05 16:10:13
Key Financial Figures
- $35,000,000 — ompany did not meet the minimum MVLS of $35,000,000 required for continued listing on The N
Filing Documents
- form8-k.htm (8-K) — 39KB
- 0001493152-24-026349.txt ( ) — 251KB
- bctx-20240703.xsd (EX-101.SCH) — 4KB
- bctx-20240703_def.xml (EX-101.DEF) — 26KB
- bctx-20240703_lab.xml (EX-101.LAB) — 36KB
- bctx-20240703_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams July 5, 2024 William V. Williams President and Chief Executive Officer